OR WAIT null SECS
February 25, 2016.
The Parkinson’s disease (PD) market is to expand from $2.1 billion in 2014 to $3.2 billion by 2021 (a CAGR of 5.7%), according to a report from GBI Research. The growth will remain moderate, the company states, because "game-changing treatments will not be available for the foreseeable future".
Key PD market products, including, Azilect, Neupro, and Stalevo, will lose patent protection during the forecast period, but new entrants are expected to offset the generic erosion. According to GBI analyst Parnjeet Baines, four new levodopa formulations are expected to enter the market by 2021, "each designed to improve off-episodes in advanced Parkinson’s disease patients by providing continuous drug administration.”
However, with various unmet needs remaining and a cure yet to be found, "game-changing products are far from being realized, and ... symptom-relieving therapies will continue to dominate the market through to 2021", Baines added.